Sector
PharmaceuticalsOpen
₹11.81Prev. Close
₹11.53Turnover(Lac.)
₹0.61Day's High
₹11.81Day's Low
₹11.1152 Week's High
₹24.8252 Week's Low
₹9.64Book Value
₹2.43Face Value
₹10Mkt Cap (₹ Cr.)
9.38P/E
0EPS
0Divi. Yield
07 Sep 2024
12:00 AM
AGM
Announcement Date: 07 Sep, 2024
19 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 8.13 | 8.13 | 8.13 | 8.13 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.31 | 2.73 | 2.83 | 3.22 |
Net Worth | 2.82 | 10.86 | 10.96 | 11.35 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 8.16 | 197.39 | 79.71 | 61.88 |
yoy growth (%) | -95.86 | 147.63 | 28.8 | -1.67 |
Raw materials | -3.95 | -154.62 | -57.59 | -40.72 |
As % of sales | 48.36 | 78.33 | 72.24 | 65.8 |
Employee costs | -1.05 | -5.35 | -3.32 | -3.34 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.13 | 0.71 | 0.68 | 1.13 |
Depreciation | -0.28 | -1.95 | -1.68 | -1.7 |
Tax paid | 0.8 | -1.28 | 0 | -0.62 |
Working capital | -19.52 | -3.33 | 2.94 | 3.15 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -95.86 | 147.63 | 28.8 | -1.67 |
Op profit growth | -78.18 | 5.72 | -0.76 | -7.62 |
EBIT growth | -74.28 | -5.76 | 2.65 | -15.72 |
Net profit growth | -267.66 | -183.02 | 34.97 | -39.65 |
| Particulars (Rupees in Crores.) | Mar-2012 |
|---|---|
Gross Sales | 78.91 |
Excise Duty | 0 |
Net Sales | 78.91 |
Other Operating Income | 6.88 |
Other Income | 0.25 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,679.2 | 94.11 | 4,03,076.28 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,544.5 | 78.74 | 1,73,924.39 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,504.2 | 24.66 | 1,21,456.43 | 1,485.4 | 1.06 | 4,254.47 | 397.42 |
Dr Reddys Laboratories Ltd DRREDDY | 1,320.9 | 20.6 | 1,10,189.83 | 1,200.7 | 0.61 | 5,546.3 | 345.81 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,154.3 | 56.03 | 1,06,756.13 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
S Murali Krishna Murthy
Non Executive Director
S Balaji Venkateswarlu
Whole Time Director & CFO
S Srinivas Kumar
Independent Director
B Gopal Reddy
Independent Director
Murali Krishna Rayaprolu
Independent Director
Pottur Sujatha
Non Executive Director
Pramod Dnyandeo Wag He
Non Executive Director
Shashikant Shankarrao Igave
Non Executive Director
Rutvikbhai Mukeshbhai Beladiya
Independent Director
Smitaben Suthar
Independent Director
Pratik Bharatbhai Panchal
Whole Time Director
Ramesh Joshi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ortin Laboratories Ltd
Summary
Ortin Laboratories Limited was incorporated in October, 1986 with a nominal capital of Rs 1 lakh to offer quality Drugs and Medicines to the suffering mankind. The Company is a leading and predominant Pharmaceutical Manufacturer of Drugs and Medicines in India. The company is engaged in manufacture of Pharma formulations. They manufacture a range of pharmaceutical formulations of tablets, capsules, syrups, dry powders, and ointments in India. The company is having their manufacturing unit at Medak in Andhra Pradesh, which is equipped with technically modern manufacturing facilities to produce complete range of Pharmaceutical Formulations.The company offer anti arthritic drugs, antibiotics, chemo therapeutics, analgesics and antipyretics, cardiac and cardio vascular drugs, anti diarroheal drugs, anti depressants, anti hypertensive, anti aids, anti tuberculosis drugs, gynaecological drugs, antibiotics, anti diabetic, antacids anti ulcer drugs, anti allergics, anti-cold, decongestants, antioxidents, vitamins, minerals, anti bacterial drugs, anti emetics, anti helmenthetics, nutritional supplements and protein, and appetizers. They also produce dental, ophthalmology, pediatric, diuretics, dermatology, psychiatry, and ENT drugs. The company constructed a Factory in a spacious area of 25,000 sq feet with all ultra-modern infrastructure as per the WHO GMP Standards to manufacture the complete range of Pharmaceutical Formulations of tablets capsules syrups dry powders & ointments. Du
Read More
What is the Ortin Global Ltd share price today?
The Ortin Global Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹11.54 today.
What is the Market Cap of Ortin Global Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ortin Global Ltd is ₹9.38 Cr. as of 09 Jun ‘25
What is the PE and PB ratio of Ortin Global Ltd?
The PE and PB ratios of Ortin Global Ltd is 0 and 4.64 as of 09 Jun ‘25
What is the 52 Week High and Low of Ortin Global Ltd?
The 52-week high/low is the highest and lowest price at which a Ortin Global Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ortin Global Ltd is ₹9.64 and ₹24.82 as of 09 Jun ‘25
What is the CAGR of Ortin Global Ltd?
Ortin Global Ltd's CAGR for 5 Years at -3.11%, 3 Years at -22.32%, 1 Year at -35.41%, 6 Month at -40.57%, 3 Month at -2.54% and 1 Month at 8.16%.
What is the shareholding pattern of Ortin Global Ltd?
The shareholding pattern of Ortin Global Ltd is as follows:
Promoters - 1.23 %
Institutions - 6.53 %
Public - 92.24 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.